Special Issue

In the Race against Polymicrobial Biofilms: Current Research and New Breakthroughs for the Clinic

Message from the Guest Editors

This Special Issue is dedicated to increasing our knowledge on the role of polymicrobial biofilms in clinical practice, aiming at advancing the current understanding of the aspects related to those foreign structures and solutions to fight them. In short, this Special Issue aims to provide a platform for researchers to describe, among others, the following subjects:

- Study of microbial-microbial (including multi-kingdom) and microbial-host interactions in the polymicrobial biofilm communities that often govern such infections;
- Current antimicrobial therapies and exploitation of novel therapeutic approaches (e.g., involving antibiotic and/or non-antibiotic strategies; phage therapy) targeting polymicrobial biofilms and aiming to reduce the burden associated with polymicrobial consortia;
- Studies addressing the mechanisms underlying AMR in polymicrobial consortia and their persistent colonization of biotic/non-biotic surfaces;
- Research on the problem of antimicrobial resistance associated with polymicrobial biofilms and ways to counteract its emergence.

Guest Editors

Dr. Susana Patrícia Lopes

CEB-Centre of Biological Engineering, LIBRO-Laboratory of Research in Biofilms Rosário Oliveira, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal

Dr. Diana Alves

CEB - Centre of Biological Engineering, LIBRO - Laboratory of Research in Biofilms Rosário Oliveira, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal

Deadline for manuscript submissions

closed (15 July 2022)



an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



mdpi.com/si/88389

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

